Clinical trial
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
NCT00122473 · Dermatologic Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00122473 |
|---|---|
| Title | Imatinib in Dermatofibrosarcoma Protuberans (DFSP) |
| Official title | Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans |
| Lead sponsor | Dermatologic Cooperative Oncology Group, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Dermatofibrosarcoma |
| Intervention type | Drug |
| Interventions | Imatinib (Glivec) |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| Completion | Jan 1, 2007 |
| First posted | Jul 22, 2005 |
| Last update posted | Jul 29, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: